In the evolving landscape of diabetes management, novel therapies like semaglutide and retatrutide are gaining traction. These agents, belonging to the glucagon-like peptide-1 (GLP-1) receptor agonist group, offer https://hassanvetc651693.blogproducer.com/46698790/semaglutide-vs-retatrutide-a-novel-comparison-in-diabetes-management